Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

LL-37vsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BPhase 3HUMAN-REVIEWED25/54 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Membrane disruptionPrimary mechanismLu 2026He 2026
Innate immunityHost defense rolePinheiro 2026Zhang 2026
Endogenous · Secreted at inflammation sites
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
Once weeklyFrequency
Phase 3Development stageRubino 2026
GLP-1/GCGRDual targetZimmermann 2026
SQ · Once Weekly

01Mechanism of Action

Parameter
LL-37
Survodutide
Primary target
Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026Lu 2026
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Antibody development

02Dosage Protocols

Parameter
LL-37
Survodutide
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
Evidence basis
In vitro, animal models, human observational
Phase 2 RCT (obesity) · Phase 3 ongoing
Standard dose
Not yet disclosed (Phase 3 ongoing)
SYNCHRONIZE Phase 3 program underway.Rubino 2026
Frequency
Once weekly
Route
SubcutaneousYathindra 2026
Phase 2 findings
Significant weight loss and metabolic marker improvementYathindra 2026
MASH indication
Under investigation for MASH-cirrhosisPatil 2026Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter
LL-37
Survodutide
Primary fat target
Total body weight, visceral adipose tissue
Weight loss mechanism
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
MRI-PDFF reduction
Hepatic fat reduction demonstrated in MASH trialsAndonie 2026
Network meta-analysis
Favorable efficacy profile vs other glucagon receptor agonists
Hepatic requirement
Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026
Energy expenditure
Increased energy expenditure contributes to weight lossZimmermann 2026
Comparative efficacy
Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter
LL-37
Survodutide
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Biofilm formation risk
LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
GI symptoms
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
Expected with subcutaneous administration
Glucagon-related effects
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
LL-37
Survodutide
  • ·Personal or family history of medullary thyroid carcinoma (class effect)
  • ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
LL-37
  • ·Active autoimmune disease (theoretical immune dysregulation)
Survodutide
  • ·Severe GI disease (inflammatory bowel disease, gastroparesis)
  • ·History of pancreatitis
  • ·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter
LL-37
Survodutide
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.